Seasonal affective disorder (SAD) has been recognized and included in the diagnostic classification system of the Diagnostic and Statistical Manual for Mental Disorders, Fourth Edition, as a major depressive disorder with seasonal pattern. Seasonality, means changing weathers highly affects people all over the world. Moreover, increasing incidence of seasonal affective disorder is expected to boost the market growth. For instance, according to an article published by the National Center for Biotechnology Information (NCBI), in October 2020, reports that around 14% of the adult in the U.S. population suffers from a lesser form of seasonal mood changes, known as winter blues.
The global seasonal affective disorder market is estimated to be valued at US$ 544.7 million in 2020 and is expected to exhibit a CAGR of 5.5% during the forecast period (2020-2027).
Figure 1. Global Seasonal Affective Disorder Market Share (%), by Region, 2020
Increasing cases of seasonal affective disorder is expected to propel growth of the global seasonal affective disorder market
The increasing cases of seasonal affective disorder is expected to boost the market growth over the forecast period. For instance, according to an article published by the Royal College of Psychiatrists, in April 2015, reports that around 3 out of 100 people have significant winter depressions in the U.K.
However, side effects of seasonal affective disorder medication such as Bupropion is expected to hinder the market growth. For instance, according to an article published by the National Center for Biotechnology Information (NCBI), in October 2020, reports that the drug Bupropion, which is approved by the U.S. FDA exhibit several side effects such as ophthalmologic including blurred vision; central nervous system including insomnia, headache, agitation, dizziness; dermatologic such as diaphoresis, and others.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2019 | Market Size in 2020: | US$ 544.7 Mn |
| Historical Data for: | 2016 to 2019 | Forecast Period: | 2020 to 2027 |
| Forecast Period 2020 to 2027 CAGR: | 5.5% | 2027 Value Projection: | US$ 794.6 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Pfizer, Inc., GlaxoSmithKline plc, Johnson & Johnson Services Inc., Novartis AG, Sanofi, Teva Pharmaceutical Industries Ltd., Eli Lily and Company, AbbVie Inc., F. Hoffmann-La Roche AG, Mylan, Inc., Bausch Health, Koninklijke Philips N.V., Bayer AG, Allergan, Bristol-Myers Squibb, and Henry Schein Inc. |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Figure 2. Global Seasonal Affective Disorder Market Share (%), by Type, 2020
Increasing cases of seasonal affective disorder (SAD) in North America is expected to boost the market growth
North America is expected to hold dominant position in the global seasonal affective disorder market, owing to increasing cases of seasonal affective disorder (SAD) in the region. For instance, according to an article published by the Boston University, in October 2019, reports that 10 million U.S. populace are affected by seasonal affective disorder, with women 4 times more likely to be diagnosed than men.
Global Seasonal Affective Disorder Market – Impact of Coronavirus (COVID-19) Pandemic
The coronavirus (COVID-19) pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses in all sectors. The private healthcare is one such sector, which has been impacted significantly by the COVID-19 pandemic.
The lockdown in various countries due to the pandemic has placed an economic burden on the healthcare sector. Moreover, the coronavirus pandemic has hampered the development, production, and supply of drugs and other healthcare products and affected growth of healthcare businesses of various companies across the globe.
As a result, the impact of the COVID-19 pandemic is also expected to limit growth of the global seasonal affective disorder market during the forecast period.
Key Players
Major players operating in the global seasonal affective disorder market include Pfizer, Inc., GlaxoSmithKline plc, Johnson & Johnson Services Inc., Novartis AG, Sanofi, Teva Pharmaceutical Industries Ltd., Eli Lily and Company, AbbVie Inc., F. Hoffmann-La Roche AG, Mylan, Inc., Bausch Health, Koninklijke Philips N.V., Bayer AG, Allergan, Bristol-Myers Squibb, and Henry Schein Inc., among others.
Seasonal affective disorder (SAD) is a form of depression that people experience at a particular time of year or during a particular season. The change in the season highly affects the mood and energy levels, and lead to symptoms of depression that have a significant impact on day-to-day life.
Market Dynamics
Rising incidence of seasonal affective disorder (SAD) is expected to drive seasonal affective disorder market growth over the forecast period. For instance, according to an article published by the Hindawi Publishing Corporation-Depression Research and Treatment, in December 2015, reports that the people who lives farthest from the equator in northern latitudes are most susceptible towards SAD, for instance, in the U.S., 1.4% of those who live in Florida and 9.9% living in Alaska experience seasonal affective disorder.
However, side effects of seasonal affective disorder medication such as Bupropion is expected to hinder the market growth. For instance, according to an article published by the National Center for Biotechnology Information (NCBI), in October 2020, reports that the drug Bupropion, which is approved by the U.S. FDA exhibit several side effects such as tachycardia (cardiovascular disease), rhinitis and pharyngitis (respiratory diseases), and others.
Key features of the study:
Detailed Segmentation:
“*” marked represents similar segmentation in other categories in the respective section.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients